Kyu Kwang Kim
Overview
Explore the profile of Kyu Kwang Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
402
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khazan N, Quarato E, Singh N, Snyder C, Moore T, Miller J, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444542
Small-molecule inhibitors of PD-L1 are postulated to control immune evasion in tumors similar to antibodies that target the PD-L1/PD-1 immune checkpoint axis. However, the identity of targetable PD-L1 inducers is...
2.
Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang J, Khoury J, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358657
Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source of tumor material that can be obtained via a venipuncture (also known as...
3.
Moore R, Khazan N, Coulter M, Singh R, Miller M, Sivagnanalingam U, et al.
Obstet Gynecol
. 2022 Sep;
140(4):631-642.
PMID: 36075062
Objective: To evaluate the detection of malignancy in women with a pelvic mass by using multiplexed gene expression analysis of cells captured from peripheral blood. Methods: This was an IRB-approved,...
4.
Khazan N, Kim K, Hansen J, Singh N, Moore T, Snyder C, et al.
J Med Chem
. 2022 Apr;
65(8):6039-6055.
PMID: 35404047
Vitamin-D receptor (VDR) mRNA is overexpressed in neuroblastoma and carcinomas of lung, pancreas, and ovaries and predicts poor prognoses. VDR antagonists may be able to inhibit tumors that overexpress VDR....
5.
Blackman A, Mitchell J, Rowswell-Turner R, Singh R, Kim K, Eklund E, et al.
Tumour Biol
. 2021 Dec;
43(1):355-365.
PMID: 34957977
Background: The measurement of serum HE4 levels has emerged as a sensitive and specific biomarker for epithelial ovarian cancers (EOCs). However, serum levels in women diagnosed with various histologic subtypes...
6.
Rowswell-Turner R, Singh R, Urh A, Yano N, Kim K, Khazan N, et al.
J Immunol
. 2021 Apr;
206(10):2478-2488.
PMID: 33903172
Ovarian cancer is a highly fatal malignancy characterized by early chemotherapy responsiveness but the eventual development of resistance. Immune targeting therapies are changing treatment paradigms for numerous cancer types but...
7.
Kim K, Turner R, Khazan N, Kodza A, Jones A, Singh R, et al.
PLoS One
. 2020 May;
15(5):e0232253.
PMID: 32365084
Proteases have been implicated in the tumorigenesis and aggressiveness of a variety of cancer types. In fact, proteases have proven to be very clinically useful as tumor biomarkers in the...
8.
Kim K, Singh R, Khazan N, Kodza A, Singh N, Jones A, et al.
Sci Rep
. 2020 Feb;
10(1):3241.
PMID: 32094384
Forchlorfenuron (FCF) is a synthetic plant cytokinin widely used in agriculture to promote fruit size, that paradoxically inhibits proliferation, migration, and invasion in human cancer cell lines. FCF has also...
9.
Rowswell-Turner R, Rutishauser J, Kim K, Khazan N, Sivagnanalingam U, Jones A, et al.
Transl Oncol
. 2019 May;
12(7):917-924.
PMID: 31082584
Advanced clear cell ovarian cancer (CCOC) is a highly fatal malignancy with a scarcity of effective treatment options. CCOC is inherently chemotherapy resistance, but the exact mechanism of this resistance...
10.
Kim K, Han A, Yano N, Ribeiro J, Lokich E, Singh R, et al.
Sci Rep
. 2015 Nov;
5:15911.
PMID: 26568478
Cisplatin and its analogs are among the most widely used chemotherapeutic agents against various types of cancer. It is known that cisplatin can activate epidermal growth factor receptor (EGFR), which...